210
Participants
Start Date
September 1, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Yueju Pill + Standard Anti-tumor Therapy
Group A (Intervention): Standard therapy + Yueju Pill (6-9 g per dose, twice daily, orally until disease progression or intolerable toxicity).
Placebo + Standard anti-tumor therapy
Group B (Control): Standard therapy + placebo (identical in appearance, packaging, dosage, and administration frequency to Yueju Pill).
Zhongshan hospital Fudan University, Shanghai
Shanghai Zhongshan Hospital
OTHER
Shanghai Geriatric Medical Center
OTHER
Minhang Central Hospital
UNKNOWN
Xuhui Central Hospital, Shanghai
OTHER
Fudan University
OTHER